Companies CareDx, Inc.
CareDx (CDNA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me CareDx, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers39th pct.Of 19 peer CEOs
CEO pay, last three years
- $9,424,329FY2024
- $7,179,699FY2025
CEO total pay was $7,179,699 in fiscal 2025, down from $9,424,329 in fiscal 2024.
FY2025: salary $693,269 · bonus $0 · stock awards $5,622,638 · option awards $0
Executives and directors
Abhishek Jain · CFOJessica Meng · CCOJohn Hanna · CEOKeith Kennedy · CFONathan Smith · CFOJeffrey Novack · General CounselArthur A. Torres · Independent DirectorChristine M. Cournoyer · Independent DirectorFred E. Cohen, M.D., D. Phil · Independent DirectorGeorge W. Bickerstaff, III · Independent DirectorHannah A. Valantine, M.D · Independent DirectorMichael D. Goldberg · Chair of the BoardPeter Maag, Ph.D · Independent DirectorR. Bryan Riggsbee · Independent DirectorSuresh Gunasekaran · Independent DirectorWilliam A. Hagstrom · Former director (through FY2025)
Frequently asked questions
Who was the highest-paid executive at CareDx, Inc. in fiscal 2025?
As disclosed, John Hanna (President and Chief Executive Officer) was the highest-paid executive at CareDx, Inc. in fiscal 2025, with total compensation of $7,179,699.
How does CareDx, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Hanna's total compensation ranked at the 39th percentile of CareDx, Inc.'s disclosed peer group.
What is CareDx, Inc.'s CEO-to-median employee pay ratio?
As disclosed, CareDx, Inc.'s CEO-to-median employee pay ratio was 48:1.
How did shareholders vote on CareDx, Inc.'s executive compensation?
As disclosed, 95.34% of shareholders supported CareDx, Inc.'s executive compensation in the latest say-on-pay vote.
How much does CareDx, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, CareDx, Inc. reported total board compensation of $2,809,087 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Hanna | $693,269 | $0 | $5,622,638 | $0 | $852,515 | $0 | $11,277 | $7,179,699 |
| President and Chief Executive Officer | ||||||||
| Keith Kennedy | 587,606 | 0 | 2,162,552 | 0 | 430,260 | 0 | 38,813 | 3,219,231 |
| Chief Operating Officer and Chief Financial Officer | ||||||||
| Abhishek Jain | 282,100 | 0 | 1,557,034 | 0 | 309,526 | 0 | 489,274 | 2,637,934 |
| Former Chief Financial Officer | ||||||||
| Jessica Meng | 485,414 | 0 | 1,730,053 | 0 | 353,683 | 0 | 10,230 | 2,579,380 |
| Chief Commercial Officer | ||||||||
| Jeffrey Novack | 361,923 | 0 | 648,758 | 0 | 216,394 | 0 | 12,477 | 1,239,552 |
| General Counsel and Secretary | ||||||||
| Nathan Smith | 141,539 | 0 | 724,200 | 0 | 91,643 | 0 | 10,577 | 967,959 |
| Former Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Hanna | $7,179,699 | $9,424,329 | — | ↓ −2,244,630 |
| Keith Kennedy | 3,219,231 | 4,512,215 | — | ↓ −1,292,984 |
| Abhishek Jain | 2,637,934 | 2,762,710 | 3,094,707 | ↓ −124,776 |
| Jessica Meng | 2,579,380 | 3,392,528 | — | ↓ −813,148 |
| Jeffrey Novack | 1,239,552 | 1,276,844 | — | ↓ −37,292 |
| Nathan Smith | 967,959 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The executive compensation program is designed to attract, develop, and retain a highly-qualified management team by aligning business objectives with stockholder interests and emphasizing pay for performance. The program structures compensation with a substantial majority of NEO compensation as at-risk, variable pay to facilitate the successful execution of business strategy and drive long-term stockholder value.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Keith Kennedy | RSU | 2025-03-23 | — | — | 77,195 | — | $2,162,552 |
| Abhishek Jain | RSU | 2025-03-23 | — | — | 55,580 | — | 1,557,034 |
| John Hanna | RSU | 2025-03-23 | — | — | 200,706 | — | 5,622,638 |
| Nathan Smith | RSU | 2025-08-07 | — | — | 42,000 | — | 724,200 |
| Jessica Meng | RSU | 2025-03-23 | — | — | 61,756 | — | 1,730,053 |
| Jeffrey Novack | RSU | 2025-03-23 | — | — | 23,158 | — | 648,758 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Keith Kennedy | $2,162,552 | $0 | $0 | 0.0% |
| Abhishek Jain | 1,557,034 | 0 | 0 | 0.0% |
| John Hanna | 5,622,638 | 0 | 0 | 0.0% |
| Nathan Smith | 724,200 | 0 | 0 | 0.0% |
| Jessica Meng | 1,730,053 | 0 | 0 | 0.0% |
| Jeffrey Novack | 648,758 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Abhishek Jain | Option | 83 | 25.78 | — |
| Jeffrey Novack | Option | 179 | 37.25 | — |
| Abhishek Jain | Option | 212 | 32.55 | — |
| Jeffrey Novack | Option | 348 | 26.29 | — |
| Abhishek Jain | RSU | 500 | — | 9,420 |
| Abhishek Jain | RSU | 637 | — | 12,001 |
| Abhishek Jain | Option | 1,042 | 24.07 | — |
| Jeffrey Novack | RSU | 1,787 | — | 33,667 |
| Jeffrey Novack | RSU | 2,913 | — | 54,881 |
| Jeffrey Novack | RSU | 3,750 | — | 70,650 |
| Abhishek Jain | RSU | 3,750 | — | 70,650 |
| Jeffrey Novack | RSU | 5,000 | — | 94,200 |
| Abhishek Jain | RSU | 5,537 | — | 104,317 |
| Jeffrey Novack | PSU | 9,925 | — | 186,987 |
| Abhishek Jain | Option | 12,604 | 18.47 | — |
| Abhishek Jain | Option | 12,863 | 15.66 | — |
| Nathan Smith | PSU | 18,000 | — | 339,120 |
| Jeffrey Novack | RSU | 23,158 | — | 436,297 |
| Abhishek Jain | PSU | 23,820 | — | 448,769 |
| Jessica Meng | PSU | 26,467 | — | 498,638 |
| Jeffrey Novack | RSU | 27,804 | — | 523,827 |
| Keith Kennedy | PSU | 33,083 | — | 623,284 |
| Jessica Meng | RSU | 39,432 | — | 742,899 |
| Nathan Smith | RSU | 42,000 | — | 791,280 |
| Abhishek Jain | RSU | 42,550 | — | 801,642 |
| Jessica Meng | Option | 51,898 | 29.43 | — |
| Keith Kennedy | RSU | 52,575 | — | 990,513 |
| Abhishek Jain | RSU | 55,580 | — | 1,047,127 |
| Jessica Meng | RSU | 61,756 | — | 1,163,483 |
| Keith Kennedy | Option | 69,198 | 29.43 | — |
| Abhishek Jain | RSU | 72,717 | — | 1,369,988 |
| Keith Kennedy | RSU | 77,195 | — | 1,454,354 |
| John Hanna | PSU | 86,017 | — | 1,620,560 |
| John Hanna | RSU | 200,706 | — | 3,781,301 |
| John Hanna | RSU | 365,853 | — | 6,892,671 |
| John Hanna | Option | 408,745 | 8.2 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Suresh GunasekaranIndependent · Governance and Nominating Committee · Partial-year service · Newly elected | $9,647 | $399,990 | $0 | $0 | $0 | $409,637 |
| Michael D. GoldbergIndependent · Board Chair · Governance and Nominating Committee (Chair) | 138,736 | 224,995 | 0 | 0 | 0 | 363,731 |
| Christine M. CournoyerIndependent · Audit and Finance Committee · Compensation and Human Capital Committee (Chair) | 72,747 | 224,995 | 0 | 0 | 0 | 297,742 |
| George W. Bickerstaff IIIIndependent · Audit and Finance · Governance and Nominating | 70,247 | 224,995 | 0 | 0 | 0 | 295,242 |
| R. Bryan RiggsbeeIndependent · Audit and Finance Committee (Chair) | 67,747 | 224,995 | 0 | 0 | 0 | 292,742 |
| Hannah A. Valantine, M.DIndependent · Governance and Nominating · Technology and Innovation (Chair) | 62,747 | 224,995 | 0 | 0 | 0 | 287,742 |
| Arthur A. TorresIndependent · Governance and Nominating | 57,747 | 224,995 | 0 | 0 | 0 | 282,742 |
| Fred E. Cohen, M.D., D. PhilIndependent · Governance and Nominating Committee · Technology and Innovation Committee | 52,747 | 224,995 | 0 | 0 | 0 | 277,742 |
| Peter Maag, Ph.DIndependent · Technology and Innovation · Governance and Nominating · Partial-year service | 52,747 | 224,995 | 0 | 0 | 0 | 277,742 |
| William A. HagstromIndependent · Departed during FY | 24,025 | 0 | 0 | 0 | 0 | 24,025 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $225,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | 3x annual cash retainer |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $609,137 |
| Equity awards (grant-date value) | $2,199,950 |
| All other compensation | $0 |
| Total cost of the board | $2,809,087 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names CareDx as a peer
Companies that benchmark against CDNA
15 companies name CDNA as a compensation peer
- Adaptive Biotechnologies CorpADPTFY2025
- Avid Bioservices, Inc.CDMOFY2024
- CERUS CORPCERSFY2025
- Chrome Holding Co.MEFY2024
- Fulgent Genetics, Inc.FLGTFY2025
- GeneDx Holdings Corp.WGSFY2025
- MIMEDX GROUP, INC.MDXGFY2025
- NEOGENOMICS INCNEOFY2025
- Outset Medical, Inc.OMFY2025
- Pacira BioSciences, Inc.PCRXFY2025
- Personalis, Inc.PSNLFY2025
- Sight Sciences, Inc.SGHTFY2025
- STANDARD BIOTOOLS INC.LABFY2025
- Twist Bioscience CorpTWSTFY2025
- VERACYTE, INC.VCYTFY2025
Each company listed discloses CDNA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDNA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
PACB Pacific Biosciences of California,VCYT Veracyte, Inc.CSTL Castle Biosciences, Inc.CTKB Cytek Biosciences, Inc.NEO NeoGenomics, Inc.QTRX Quanterix CorporationATRC AtriCure, Inc.ADPT Adaptive Biotechnologies Corp.ATEC Alphatec Spine, Inc.CERS Cerus CorporationFLGT Fulgent Genetics, Inc.GH Guardant Health, Inc.IRTC iRhythm Technologies, Inc.TWST Twist Bioscience CorporationMRVI Maravai Lifesciences, Inc.NTRA Natera, Inc.MYGN Myriad Genetics, Inc. Standard Bio Tools, Inc.TMDX TransMedics Group
Peer reciprocity
The companies CareDx, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Veracyte, Inc. (VCYT)107NeoGenomics, Inc. (NEO)108Adaptive Biotechnologies Corp. (ADPT)109Cerus Corporation (CERS)110Fulgent Genetics, Inc. (FLGT)111
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Natera, Inc. | 2025 | Steven Chapman | $853,710 | $12,979,558 | $0 | $1,114,151 | $14,957,319 |
| 2 | Twist Bioscience Corporation | 2025 | Emily Leproust | 720,000 | 11,998,134 | 0 | 932,918 | 13,781,570 |
| 3 | iRhythm Technologies, Inc. | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 4 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 5 | Alphatec Spine, Inc. | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 6 | Maravai Lifesciences, Inc. | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 7 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 8 | NeoGenomics, Inc. | 2025 | Tony Zook | 601,539 | 3,999,997 | 3,998,235 | 513,400 | 9,127,092 |
| 9 | Adaptive Biotechnologies Corp. | 2025 | Chad Robins | 698,258 | 7,675,100 | 0 | 703,380 | 9,081,690 |
| 10 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 11 | Veracyte, Inc. | 2025 | Marc Stapley | 700,000 | 5,890,877 | 0 | 826,000 | 7,421,877 |
| 12 | CareDx, Inc. | 2025 | John Hanna | 693,269 | 5,622,638 | 0 | 852,515 | 7,179,699 |
| 13 | Castle Biosciences, Inc. | 2025 | Derek Maetzold | 751,350 | 4,977,208 | 0 | 1,036,863 | 6,786,771 |
| 14 | Fulgent Genetics, Inc. | 2025 | Ming Hsieh | 1,000,000 | 4,000,000 | 0 | 1,207,000 | 6,207,000 |
| 15 | Myriad Genetics, Inc. | 2025 | Samraat Raha | 856,901 | 3,989,729 | 0 | 814,660 | 5,686,740 |
| 16 | Quanterix Corporation | 2025 | Masoud Toloue | 670,950 | 1,170,000 | 2,729,998 | 674,172 | 5,250,745 |
| 17 | Cytek Biosciences, Inc. | 2025 | Wenbin Jiang | 620,000 | 2,000,000 | 2,000,000 | 485,211 | 5,120,061 |
| 18 | Pacific Biosciences of California, | 2025 | Christian Henry | 748,250 | 1,151,013 | 1,696,278 | 714,305 | 4,309,846 |
| 19 | Cerus Corporation | 2025 | William Greenman | 793,750 | 2,242,585 | 0 | 756,000 | 3,794,657 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| CareDx, Inc. | not disclosed | RSU 70 · PRSU 30 | No | Alpine Rewards |
| Adaptive Biotechnologies Corp. | not disclosed | RSU 50 · PSU 50 | not disclosed | Semler Brossy Consulting Group, LLC |
| Alphatec Spine, Inc. | 157% | PSU 50 · RSU 50 | No | Compensia |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Castle Biosciences, Inc. | 138% | RSU 50 · PSU 50 | No | AON (AON's Human Capital Solutions Practice, a division of AON plc) |
| Cerus Corporation | 126% | not disclosed | No | Alpine |
| Cytek Biosciences, Inc. | 78.4% | RSU 50 · Options 50 | not disclosed | Meridian Compensation Partners, LLC |
| Fulgent Genetics, Inc. | 120.7% | PSU 60 · RSU 40 | No | USI |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 · Option 35 | No | Aon |
| iRhythm Technologies, Inc. | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| Maravai Lifesciences, Inc. | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Myriad Genetics, Inc. | 89% | RSU 50 · PSU 50 | Yes | Mercer, LLC |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| NeoGenomics, Inc. | 60% | RSU 50 · Options 50 | not disclosed | WTW |
| Pacific Biosciences of California, | 95% | not disclosed | not disclosed | Aon Human Capital Solutions |
| Quanterix Corporation | 95% | Options 70 · RSU 30 | not disclosed | PayGov |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Twist Bioscience Corporation | 129.6% | PSU 50 · RSU 50 | No | not disclosed |
| Veracyte, Inc. | 118% | PSU 50 · RSU 50 | No | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 39,387,247 | 1,905,070 | 20,705 | 95.34% | Passed |
| 2025 | 2025-06-12 | 40,012,994 | 3,694,527 | 23,851 | 91.55% | Passed |
| 2024 | 2024-06-13 | 38,902,912 | 1,639,617 | 40,225 | 95.96% | Passed |
| 2023 | 2023-06-15 | 38,609,980 | 1,801,445 | 59,166 | 95.54% | Passed |
| 2022 | 2022-06-15 | 44,699,515 | 1,700,604 | 24,752 | 96.33% | Passed |
| 2021 | 2021-06-15 | 41,311,677 | 3,896,382 | 34,628 | 91.31% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | 95.34%a |
| 2025 | 2025-06-12 | 91.55%b |
| 2024 | 2024-06-13 | 95.96%c |
a. Approved under the standard stated in the filing — “2, the abstention will have the same effect as a vote AGAINST the proposal.”.
b. Approved under the standard stated in the filing — “1 will be determined by a plurality vote (see the next question below for an explanation of what a plurality vote means), abstentions will have no impact on the outcome of such proposal as long as a quorum exists.”.
c. Approved under the standard stated in the filing — “1 will be determined by a plurality vote (see the next question below for an explanation of what a plurality vote means), abstentions will have no impact on the outcome of such proposal as long as a quorum exists.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 48 : 1 |
|---|---|
| CEO total compensation | $7,179,699 |
| Median employee compensation | $148,417 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Novack | Secretary and General Counsel | 2026-05-01 | D | 2,873 | $22 | $61,770 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-05-05 | D | 2,688 | 21 | 55,581 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 4,086 | 21 | 85,698 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-15 | D | 6,484 | 20 | 128,978 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-04 | D | 4,835 | 24 | 116,045 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-04 | — | 706 | — | — | 1 insider, 1 accrual row | ||
| John Hanna | Director | 2026-06-04 | A | 706 | 8 | 5,789 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-06-06 | D | 1,292 | 22 | 28,359 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | D | 21,998 | 24 | 528,443 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | D | 13,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | A | 13,618 | 8 | 111,668 | Common | Form 4 ↗ |
| Suresh Gunasekaran | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| R. Bryan Riggsbee | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| George W. Bickerstaff III | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | A | 15,676 | 8 | 128,543 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-15 | D | 12,103 | 23 | 279,728 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | D | 17,683 | 24 | 424,877 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | D | 15,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-26 | A | 100 | 8 | 820 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-26 | — | 100 | — | — | 1 insider, 1 accrual row | ||
| John Hanna | Director | 2026-06-26 | D | 100 | 29 | 2,900 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | A | 39,900 | 8 | 327,180 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | D | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | D | 39,900 | 29 | 1,166,836 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-07-01 | D | 2,930 | 29 | 85,703 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-07-01 | D | 2,411 | 29 | 70,522 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-01 | D | 8,511 | 29 | 248,947 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-07-01 | D | 997 | 29 | 29,162 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-07-02 | A | 1,746 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 7,606 | 21 | 156,379 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 28,679 | 36 | 1,036,588 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 5,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 16,048 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 7,606 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 100 | 37 | 3,655 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 5,125 | 8 | 40,795 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 118,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 68,000 | 39 | 2,652,932 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | A | 118,000 | 8 | 967,600 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 16,048 | 14 | 227,721 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 50,000 | 36 | 1,805,705 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-01 | D | 2,872 | 48 | 137,425 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-08-04 | D | 44,700 | 47 | 2,103,497 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-08-04 | D | 16,000 | 47 | 750,973 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-05 | D | 500 | 47 | 23,375 | Common | Form 4 ↗ |
| George W. Bickerstaff III | Director | 2026-08-05 | D | 20,000 | 46 | 925,700 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-05 | D | 2,188 | 46 | 100,974 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-09-12 | D | 8,220 | 52 | 430,481 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-09-12 | D | 6,688 | 52 | 350,251 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-10-01 | D | 2,619 | 66 | 173,456 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-10-01 | D | 997 | 66 | 66,031 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-10-01 | D | 8,511 | 66 | 563,684 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-10-01 | D | 3,018 | 66 | 199,882 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-10-02 | A | 588 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 58 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Novack | Secretary and General Counsel | 2026-05-01 | D | 2,873 | $22 | $61,770 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-05-05 | D | 2,688 | 21 | 55,581 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-14 | D | 4,086 | 21 | 85,698 | Common | Form 4 ↗ |
| Arthur A. Torres | Director | 2026-05-15 | D | 6,484 | 20 | 128,978 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-04 | D | 4,835 | 24 | 116,045 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-04 | D | 706 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-04 | A | 706 | 8 | 5,789 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-06-06 | D | 1,292 | 22 | 28,359 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | D | 21,998 | 24 | 528,443 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | D | 13,618 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-11 | A | 13,618 | 8 | 111,668 | Common | Form 4 ↗ |
| Suresh Gunasekaran | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| R. Bryan Riggsbee | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| George W. Bickerstaff III | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Fred E. Cohen | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-06-12 | A | 9,795 | 0 | 0 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | A | 15,676 | 8 | 128,543 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-06-15 | D | 12,103 | 23 | 279,728 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | D | 17,683 | 24 | 424,877 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-15 | D | 15,676 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-26 | A | 100 | 8 | 820 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-26 | D | 100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-26 | D | 100 | 29 | 2,900 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | A | 39,900 | 8 | 327,180 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | D | 39,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-06-29 | D | 39,900 | 29 | 1,166,836 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-07-01 | D | 2,930 | 29 | 85,703 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-07-01 | D | 2,411 | 29 | 70,522 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-01 | D | 8,511 | 29 | 248,947 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-07-01 | D | 997 | 29 | 29,162 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-07-02 | A | 1,746 | 0 | 0 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 7,606 | 21 | 156,379 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 28,679 | 36 | 1,036,588 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 5,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 16,048 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 7,606 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | D | 100 | 37 | 3,655 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 5,125 | 8 | 40,795 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 118,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 68,000 | 39 | 2,652,932 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | A | 118,000 | 8 | 967,600 | Common | Form 4 ↗ |
| Hannah Valantine | Director | 2026-07-16 | A | 16,048 | 14 | 227,721 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-07-16 | D | 50,000 | 36 | 1,805,705 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-01 | D | 2,872 | 48 | 137,425 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-08-04 | D | 44,700 | 47 | 2,103,497 | Common | Form 4 ↗ |
| Christine M. Cournoyer | Director | 2026-08-04 | D | 16,000 | 47 | 750,973 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-05 | D | 500 | 47 | 23,375 | Common | Form 4 ↗ |
| George W. Bickerstaff III | Director | 2026-08-05 | D | 20,000 | 46 | 925,700 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-08-05 | D | 2,188 | 46 | 100,974 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-09-12 | D | 8,220 | 52 | 430,481 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-09-12 | D | 6,688 | 52 | 350,251 | Common | Form 4 ↗ |
| Jessica Meng | Chief Commercial Officer | 2026-10-01 | D | 2,619 | 66 | 173,456 | Common | Form 4 ↗ |
| Jeffrey Novack | Secretary and General Counsel | 2026-10-01 | D | 997 | 66 | 66,031 | Common | Form 4 ↗ |
| John Hanna | Director | 2026-10-01 | D | 8,511 | 66 | 563,684 | Common | Form 4 ↗ |
| Keith Kennedy | CFO & COO | 2026-10-01 | D | 3,018 | 66 | 199,882 | Common | Form 4 ↗ |
| Michael D. Goldberg | Director | 2026-10-02 | A | 588 | 0 | 0 | Common | Form 4 ↗ |
Sources (111 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, John Hanna. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 7,179,699. View filing ↗
- Section 01, Keith Kennedy. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 3,219,231. View filing ↗
- Section 01, Abhishek Jain. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 2,637,934. View filing ↗
- Section 01, Jessica Meng. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 2,579,380. View filing ↗
- Section 01, Jeffrey Novack. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 1,239,552. View filing ↗
- Section 01, Nathan Smith. DEF 14A, filed 2026-04-27. Section “Summary Compensation Table” · page 71. As printed: 967,959. View filing ↗
- Section 03, Keith Kennedy RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Abhishek Jain RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, John Hanna RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nathan Smith RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jessica Meng RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jeffrey Novack RSU. DEF 14A, filed 2026-04-27. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-27. Section “CEO Pay Ratio”. As printed: 48 : 1. View filing ↗
- Section 08, Suresh Gunasekaran. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 409,637. View filing ↗
- Section 08, Michael D. Goldberg. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 363,731. View filing ↗
- Section 08, Christine M. Cournoyer. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 297,742. View filing ↗
- Section 08, George W. Bickerstaff III. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 295,242. View filing ↗
- Section 08, R. Bryan Riggsbee. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 292,742. View filing ↗
- Section 08, Hannah A. Valantine, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 287,742. View filing ↗
- Section 08, Arthur A. Torres. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 282,742. View filing ↗
- Section 08, Fred E. Cohen, M.D., D. Phil. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 277,742. View filing ↗
- Section 08, Peter Maag, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 277,742. View filing ↗
- Section 08, William A. Hagstrom. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 24,025. View filing ↗
- Section 02, Jeffrey Novack 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-05-05. Form 4, filed 2026-05-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur A. Torres 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur A. Torres 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-04. Form 4, filed 2026-06-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-04. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-04. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-06-06. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-11. Form 4, filed 2026-06-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-11. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-11. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Suresh Gunasekaran 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, R. Bryan Riggsbee 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George W. Bickerstaff III 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fred E. Cohen 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine M. Cournoyer 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael D. Goldberg 2026-06-12. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-15. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-06-15. Form 4, filed 2026-06-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-15. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-26. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-06-29. Form 4, filed 2026-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Kennedy 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Meng 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-07-01. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael D. Goldberg 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hannah Valantine 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-08-01. Form 4, filed 2026-08-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael D. Goldberg 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine M. Cournoyer 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George W. Bickerstaff III 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-08-05. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Kennedy 2026-09-12. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Meng 2026-09-12. Form 4, filed 2026-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Meng 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Novack 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Hanna 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Keith Kennedy 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael D. Goldberg 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-15. Item 5.07 · say-on-pay result. As reported: 95.34% (votes for as printed: 39,387,247). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: 91.55% (votes for as printed: 40,012,994). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: 95.96% (votes for as printed: 38,902,912). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 609,137 + equity 2,199,950 + all other 0 = 2,809,087, summed across the director compensation table rows.
- Natera, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. View filing ↗
- Twist Bioscience Corporation, Section 10b CEO total. DEF 14A, filed 2026-01-06. CEO total compensation as printed in Twist Bioscience Corporation's own proxy. As printed: 13,781,570. View filing ↗
- iRhythm Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Technologies, Inc.'s own proxy. As printed: 11,003,163. View filing ↗
- TransMedics Group, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. View filing ↗
- Alphatec Spine, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Spine, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
- Maravai Lifesciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Maravai Lifesciences, Inc.'s own proxy. As printed: 10,129,708. View filing ↗
- AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- NeoGenomics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in NeoGenomics, Inc.'s own proxy. As printed: 9,127,092. View filing ↗
- Adaptive Biotechnologies Corp., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Adaptive Biotechnologies Corp.'s own proxy. As printed: 9,081,690. View filing ↗
- Guardant Health, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. View filing ↗
- Veracyte, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Veracyte, Inc.'s own proxy. As printed: 7,421,877. View filing ↗
- CareDx, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in CareDx, Inc.'s own proxy. As printed: 7,179,699. View filing ↗
- Castle Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Castle Biosciences, Inc.'s own proxy. As printed: 6,786,771. View filing ↗
- Fulgent Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-31. CEO total compensation as printed in Fulgent Genetics, Inc.'s own proxy. As printed: 6,207,000. View filing ↗
- Myriad Genetics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in Myriad Genetics, Inc.'s own proxy. As printed: 5,686,740. View filing ↗
- Quanterix Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Quanterix Corporation's own proxy. As printed: 5,250,745. View filing ↗
- Cytek Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cytek Biosciences, Inc.'s own proxy. As printed: 5,120,061. View filing ↗
- Pacific Biosciences of California,, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Pacific Biosciences of California,'s own proxy. As printed: 4,309,846. View filing ↗
- Cerus Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. View filing ↗
- Section 10a, Veracyte, Inc. reciprocity. DEF 14A. Veracyte, Inc. names CareDx, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, NeoGenomics, Inc. reciprocity. DEF 14A. NeoGenomics, Inc. names CareDx, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Adaptive Biotechnologies Corp. reciprocity. DEF 14A. Adaptive Biotechnologies Corp. names CareDx, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Cerus Corporation reciprocity. DEF 14A. Cerus Corporation names CareDx, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Fulgent Genetics, Inc. reciprocity. DEF 14A. Fulgent Genetics, Inc. names CareDx, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗